Evolution of the management of colorectal cancer using integrative medicine.
Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. In recent years, the development of new and effective management options, such as fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), total mesorectal excision (TME) and monoclonal antibody novel "targeted" therapies has led to a considerable improvement in the outcome of this disease. In China, studies on CRC using integrative medicine (IM) have made remarkable progress. We therefore review the recent developments in CRC treatment through IM and Western medicine, including research studies such as the exploitation of Chinese herbs for the disruption of the tumor cell cycle or inhibition of tumor cell proliferation, induction of tumor cell apoptosis, improvement of the immune system, and the curative effect of chemotherapy. We also examine clinical studies such as those on special prescriptions and medicines and IM in anti-cancer therapy. Particularly, we analyze the advantages and disadvantages of management with IM, and propose a suggestion for the management of colorectal cancer with IM, such as screening for effective prescriptions. We also analyze Chinese medicine, studying the pharmacologic mechanism of its anti-cancer effect, further strengthening the study of IM on CRC.
Fujian Medical University, Fujian 350004, China.
Shao-Tang
ST
Li
Pan
P
Chi
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D055048:Integrative Medicine / Q000706:statistics & numerical data*
D000970:Antineoplastic Agents
J Clin Oncol. 2004 Jan 1;22(1):23-30
14665611
Surg Clin North Am. 1997 Feb;77(1):27-48
9092116
J Pathol. 1986 Nov;150(3):195-203
3806280
Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
17139318
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Dec;27(12):1086-9
18198641
J Gastroenterol. 2006 Mar;41(3):185-92
16699851
Cancer. 2005 Nov 15;104(10):2035-47
16206296
Ann Surg Oncol. 2007 Jun;14(6):1860-9
17356952
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9
17686822
Curr Opin Immunol. 1997 Oct;9(5):702-8
9368780
Nat Rev Immunol. 2006 Apr;6(4):295-307
16557261
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Aug;20(8):580-2
11789186
J Surg Oncol. 2006 Jul 1;94(1):68-80
16788948
JAMA. 2008 Nov 19;300(19):2277-85
19017914
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Aug;26(8):677-80
16970086
J Surg Oncol. 2005 Dec 15;92(4):347-59
16299807
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Oct;27(10):879-82
17990451
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Mar;25(3):207-9
15842137
Semin Oncol. 2000 Oct;27(5 Suppl 10):112-9
11049042
J Clin Oncol. 2005 Feb 10;23(5):1011-27
15585754
Lancet. 2005 Jan 8-14;365(9454):153-65
15639298
Annu Rev Immunol. 2003;21:807-39
12615893
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Mar;25(3):240-3
15842147
J Clin Oncol. 2005 Dec 20;23(36):9441-2
16361649
Nat Clin Pract Oncol. 2006 Jan;3(1):24-40
16407877
Cancer. 2007 Jun 1;109(11):2182-9
17429839
Di Yi Jun Yi Da Xue Xue Bao. 2005 Jan;25(1):48-52
15683997
J Clin Oncol. 2008 Dec 10;26(35):5721-7
19001325